Drugs / AVA6103
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07454642 | Mar 2026 → Jan 2029 expected | cervical adenosquamous carcinoma, colorectal cancer, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma +4 | Avacta Life Sciences Ltd | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 7
| Date | Issuer | Release |
|---|---|---|
| 2026-05-06 | Avacta Life Sciences Ltd | Results Avacta presents new comparisons of pre|CISION® payload release vs approved ADCs and AVA6207 dual payload delivery at Science Day 2026 avacta.com ↗
The Company is presenting comparative analyses of pre|CISION ® payload delivery via one of its programs, AVA6103, compared with now two approved Antibody-Drug Conjugates (ADCs). |
| 2026-04-21 | Avacta Life Sciences Ltd | Results Avacta data at AACR 2026 underline favorable profile of AVA6103 and advantages of pre|CISION® delivery platform avacta.com ↗
Presentation of additional analyses from FAP-Exd (AVA6103) study shows robust activity in PDX models with low FAP expression and more favorable kinetic profile compared to the marketed antibody-drug conjugate (ADC) Enhertu |
| 2026-02-24 | Avacta Life Sciences Ltd | Results Avacta’s pre|CISION Mechanism for Payload Delivery Shows Key Advantages Compared to an Antibody Drug Conjugate in Innovative AI-Driven Analysis avacta.com ↗
Experimental data from FAP-Exd (AVA6103) demonstrates a more favorable profile compared to the marketed Antibody Drug Conjugate (ADC) Enhertu ® |
| 2026-01-21 | Avacta Life Sciences Ltd | Regulatory Avacta Announces U.S. Food and Drug Administration Clearance of the Investigational New Drug (IND) Application for the Second pre|CISION® Medicine, FAP-Exatecan (AVA6103) avacta.com ↗
Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION ® , a tumor-activated oncology delivery platform, is pleased to announce U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application for the Company’s second program FAP-Exd (AVA6103), the first pre|CISION ® peptide drug conjugate based on the highly potent topoisomerase I inhibitor, exatecan. |
| 2025-12-18 | Avacta Life Sciences Ltd | Results Avacta reports new pharmacology data for FAP-Exd (AVA6103) avacta.com ↗
Today’s new data include the following observations: Potent tumor-specific and broad-spectrum cytotoxicity: FAP-Exd (pre|CISION exatecan) is a potent peptide drug conjugate designed to produce sustained release of active exatecan directly in the tumor via the pre|CISION bystander effect |
| 2025-04-28 | Avacta Life Sciences Ltd | Results Avacta Therapeutics Presents Preclinical and Translational Data from pre|CISION® Platform Candidates at 2025 AACR Annual Meeting avacta.com ↗
FAP-EXd (AVA6103) demonstrates tumor growth inhibition and durable complete responses in multiple therapy-resistant preclinical models |
| 2024-10-24 | Avacta Life Sciences Ltd | Results Avacta Reports Pipeline Advances with Two Novel Programs at the EORTC-NCI-AACR Molecular Targets Symposium in Barcelona avacta.com ↗
The presentations include data from two preclinical oncology assets, AVA6103 and AVA7100, from Avacta’s pipeline of pre|CISION ® product candidates. |
All press releases naming this drug 10 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AVA6103 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07454642 ↗ |
| Route | Intravenous | “administered intravenously” NCT07454642 ↗ |